Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00538733 · FLOW

Participant flow

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma · Source last updated 2021-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    26 patients started the treatment phase. Per protocol, completion of the treatment phase was defined as removal from treatment due to progression, or to pursue an alternative treatment (either a stem cell transplant, or further consolidation chemotherapy in pursuit of a transplant).
    id
    FG000
    title
    T-BiRD Therapy (All Patients)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      declined to participate
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      still on therapy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1
      type
      Removed Due to Progression of Disease
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      Removed to Pursue a Stem Cell Transplant
    4. achievements
      1. group Id
        FG000
        num Subjects
        2
      type
      Removed to Pursue Alternative Theray
    5. achievements
      1. group Id
        FG000
        num Subjects
        14
      type
      COMPLETED
    6. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    26 patients started the treatment phase. Per protocol, completion of the treatment phase was defined as removal from treatment due to progression, or to pursue an alternative treatment (either a stem cell transplant, or further consolidation chemotherapy in pursuit of a transplant).
    id
    FG000
    title
    T-BiRD Therapy (All Patients)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      declined to participate
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      still on therapy
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1
      type
      Removed Due to Progression of Disease
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      Removed to Pursue a Stem Cell Transplant
    4. achievements
      1. group Id
        FG000
        num Subjects
        2
      type
      Removed to Pursue Alternative Theray
    5. achievements
      1. group Id
        FG000
        num Subjects
        14
      type
      COMPLETED
    6. achievements
      1. group Id
        FG000
        num Subjects
        12
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice